US5688785A
(en)
*
|
1991-07-23 |
1997-11-18 |
Schering Corporation |
Substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5631365A
(en)
|
1993-09-21 |
1997-05-20 |
Schering Corporation |
Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
|
MX9606319A
(es)
*
|
1994-06-20 |
1997-05-31 |
Schering Corp |
Compuestos de acetidinonas sustituidas utiles como agentes hipocolesterolemicos.
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
US6262277B1
(en)
*
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
US6268392B1
(en)
|
1994-09-13 |
2001-07-31 |
G. D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
US5624920A
(en)
*
|
1994-11-18 |
1997-04-29 |
Schering Corporation |
Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5633246A
(en)
*
|
1994-11-18 |
1997-05-27 |
Schering Corporation |
Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
|
US5656624A
(en)
*
|
1994-12-21 |
1997-08-12 |
Schering Corporation |
4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
|
EP0862645B1
(fr)
*
|
1995-09-27 |
2003-02-05 |
Schering Corporation |
Processus de reduction microbienne stereoselective
|
EP0766962A3
(fr)
*
|
1995-10-03 |
2000-05-10 |
Beiersdorf-Lilly GmbH |
Traitement de l'athérosclérose
|
US5843938A
(en)
*
|
1995-10-03 |
1998-12-01 |
Beiersdorf-Lilly Gmbh |
Treatment of atherosclerosis
|
WO1997016455A1
(fr)
*
|
1995-10-31 |
1997-05-09 |
Schering Corporation |
2-azetidinones substituees par un sucre, utiles comme agents hypocholesterolemiants.
|
WO1997016424A1
(fr)
*
|
1995-11-02 |
1997-05-09 |
Schering Corporation |
Procede de preparation de 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl ou 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
|
ATE305781T1
(de)
|
1996-02-23 |
2005-10-15 |
Lilly Co Eli |
Non-peptidische vasopressin via antagonisten
|
US5739321A
(en)
*
|
1996-05-31 |
1998-04-14 |
Schering Corporation |
3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
|
US5886171A
(en)
*
|
1996-05-31 |
1999-03-23 |
Schering Corporation |
3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
|
US5756470A
(en)
*
|
1996-10-29 |
1998-05-26 |
Schering Corporation |
Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
|
FR2762336B1
(fr)
*
|
1997-04-21 |
1999-06-11 |
Francois Trantoul |
Procede de fabrication d'un film a motif non reproductible par lecture optique pour la protection de documents
|
US6133001A
(en)
*
|
1998-02-23 |
2000-10-17 |
Schering Corporation |
Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
|
US5919672A
(en)
*
|
1998-10-02 |
1999-07-06 |
Schering Corporation |
Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
|
WO2000034240A1
(fr)
*
|
1998-12-07 |
2000-06-15 |
Schering Corporation |
Procede relatif a la synthese d'azetidinones
|
US6207822B1
(en)
|
1998-12-07 |
2001-03-27 |
Schering Corporation |
Process for the synthesis of azetidinones
|
ATE248606T1
(de)
*
|
1998-12-23 |
2003-09-15 |
Searle Llc |
Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen
|
PT1140188E
(pt)
*
|
1998-12-23 |
2003-10-31 |
Searle Llc |
Combinacoes de inibidores do transporte de acidos biliares do ileo e de inibidores da proteina de transferencia de esteres de colesterilo para doencas cardiovasculares.
|
DK1140185T3
(da)
|
1998-12-23 |
2003-09-29 |
Searle Llc |
Kombinationer af cholesterylestertransferhæmmere og galdesyre kompleksdannende forbindelser til hjertekar indikationer
|
WO2000038722A1
(fr)
|
1998-12-23 |
2000-07-06 |
G.D. Searle & Co. |
COMBINAISONS D'INHIBITEURS DE LA PROTEINE DE TRANSFERT DE L'ESTER DE CHOLESTERYLE ET D'INHIBITEURS DE LA HMG CoA-REDUCTASE UTILISEES DANS LE CADRE DE TROUBLES CARDIO-VASCULAIRES
|
ATE242007T1
(de)
|
1998-12-23 |
2003-06-15 |
Searle Llc |
Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
|
IL143949A0
(en)
|
1998-12-23 |
2002-04-21 |
Searle Llc |
Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
|
EP1140189B1
(fr)
|
1998-12-23 |
2003-05-14 |
G.D. Searle LLC. |
Combinaisons d'inhibiteurs de transport de l'acide biliaire ileal et de derives de l'acide fibrique utilisees dans le cadre de maladies cardio-vasculaires
|
EA004877B1
(ru)
*
|
1998-12-23 |
2004-08-26 |
Джи.Ди.Сирл Ллс |
Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и агентов, секвестрирующих желчные кислоты, для сердечно-сосудистых показаний
|
ATE549412T1
(de)
|
1999-04-05 |
2012-03-15 |
Schering Corp |
Stereoselektive mikrobielle reduktion für die herstellung von 1-(4-fluorophenyl)-3(r)- 3(s)- hydroxy-3-(4-fluorophenyl)propyl) -4(s)-(4-hhydroxyphenyl)-2-azetidinon
|
US6297268B1
(en)
|
1999-11-30 |
2001-10-02 |
Schering Corporation |
Imidazoles as cholesterol lowering agents
|
EP1286984A2
(fr)
|
2000-03-10 |
2003-03-05 |
Pharmacia Corporation |
Procede de preparation de tetrahydrobenzothiepines
|
AU2001247331A1
(en)
*
|
2000-03-10 |
2001-09-24 |
Pharmacia Corporation |
Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
|
US6584357B1
(en)
*
|
2000-10-17 |
2003-06-24 |
Sony Corporation |
Method and system for forming an acoustic signal from neural timing difference data
|
WO2002036124A2
(fr)
*
|
2000-10-30 |
2002-05-10 |
Schering Corporation |
Procede de traitement
|
EP1510521A1
(fr)
*
|
2000-12-20 |
2005-03-02 |
Schering Corporation |
2-azetidinones substitués par le sucre utilisés comme agents hypocholestérolémiants
|
CN100475829C
(zh)
|
2000-12-20 |
2009-04-08 |
先灵公司 |
作为降血胆甾醇剂的糖取代的2-氮杂环丁烷酮
|
EP1593670B1
(fr)
*
|
2000-12-20 |
2007-08-08 |
Schering Corporation |
2-Azétidinones substitués par hydroxy utilisés comme hypocholestérolémiants
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
AU1609702A
(en)
*
|
2000-12-21 |
2002-07-01 |
Aventis Pharma Gmbh |
Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
|
IL156552A0
(en)
|
2000-12-21 |
2004-01-04 |
Aventis Pharma Gmbh |
Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
|
AU2006202618B2
(en)
*
|
2001-01-26 |
2007-04-19 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
PT1353694E
(pt)
*
|
2001-01-26 |
2008-03-12 |
Schering Corp |
Combinações de ezetimiba com aspirina para o tratamento de doenças vasculares
|
AU2008201609B8
(en)
*
|
2001-01-26 |
2009-01-08 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitors(s) and treatments for vascular indications
|
DK1353696T3
(da)
*
|
2001-01-26 |
2007-04-10 |
Schering Corp |
Kombinationer af peroxisomproliferatoraktiveret receptor (PPAR)-aktivator(er) og sterolabsorptionsinhibitor(er) og behandlinger til vaskulære indikationer
|
AU2007201970B2
(en)
*
|
2001-01-26 |
2008-04-17 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
AU2005246926B2
(en)
*
|
2001-01-26 |
2008-02-28 |
Merck Sharp & Dohme Corp. |
The use of substituted azetidinone compounds for the treatment of sitosterolemia
|
MXPA03006727A
(es)
*
|
2001-01-26 |
2003-10-24 |
Schering Corp |
Combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y tratamiento para indicaciones vasculares.
|
EP1911462A3
(fr)
|
2001-01-26 |
2011-11-30 |
Schering Corporation |
Combinaisons comprenant un inhibiteur d'absorption de stérol
|
RU2756946C2
(ru)
*
|
2001-01-26 |
2021-10-07 |
Мерк Шарп И Доум Корп. |
Применение замещенных азетидинонов для лечения ситостеролемии
|
AU2006203175B2
(en)
*
|
2001-01-26 |
2008-07-24 |
Organon Llc |
Combinations of peroxisome proliferator-activated receptor (PPAR) activators(s) and sterol absorption inhibitors(s) and treatments for vascular indications
|
DE60221798T2
(de)
*
|
2001-01-26 |
2008-06-05 |
Schering Corp. |
Kombinationen von gallensäure sequestriermitteln und hemmern der sterol absorption zur behandlung von kardiovaskulären indikationen
|
ES2286233T3
(es)
*
|
2001-01-26 |
2007-12-01 |
Schering Corporation |
Combinaciones de inhibidor(es) de la absorcion de esteroles con agente(s) cardiovascular(es) para el tratamiento de afecciones vasculares.
|
TWI291957B
(en)
*
|
2001-02-23 |
2008-01-01 |
Kotobuki Pharmaceutical Co Ltd |
Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
|
RS50386B
(sr)
|
2001-03-28 |
2009-12-31 |
Schering Corporation, |
Enantioselektivna sinteza intermedijarnih jedinjenja azetidinona
|
CA2447884A1
(fr)
*
|
2001-05-25 |
2002-12-05 |
Schering Corporation |
Procedes pour traiter la maladie d'alzheimer et/ou pour reguler les niveaux de peptides beta-amyloides chez un sujet
|
US20040077625A1
(en)
*
|
2001-07-25 |
2004-04-22 |
Tremont Samuel J. |
Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
US7056906B2
(en)
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
EP1429756B1
(fr)
*
|
2001-09-21 |
2006-11-22 |
Schering Corporation |
Methodes et combinaisons therapeutiques utiles pour le traitement du xanthome effectue avec des inhibiteurs d'absorption du sterol
|
EP1859796A3
(fr)
*
|
2001-09-21 |
2008-07-02 |
Schering Corporation |
Treatment de xanthoma avec des dérivés d'azétidines en tant qu'inhibiteurs d'absorption des stérols
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
BR0213501A
(pt)
*
|
2001-11-02 |
2004-08-24 |
Searle Llc |
Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato
|
KR20050044352A
(ko)
*
|
2001-11-09 |
2005-05-12 |
아테로제닉스, 인코포레이티드 |
심혈관 병리의 역전 및 예방 방법
|
US7202247B2
(en)
|
2001-12-19 |
2007-04-10 |
Atherogenics, Inc. |
1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
|
MXPA04005864A
(es)
*
|
2001-12-19 |
2004-10-29 |
Atherogenics Inc |
Derivados de charcona y su uso para tratar enfermedades.
|
FR2833842B1
(fr)
*
|
2001-12-21 |
2004-02-13 |
Aventis Pharma Sa |
Compositions pharmaceutiques a base de derives d'azetidine
|
EP1465885A4
(fr)
|
2002-01-17 |
2005-04-27 |
Pharmacia Corp |
Nouveaux composes d'alkyl/aryl hydroxy ou cetothiepine servant d'inhibiteurs du transport des acides biliaires de type ileal et de l'absorption de taurocholate
|
US20050123580A1
(en)
*
|
2002-02-28 |
2005-06-09 |
Burris Thomas P. |
Method of treating atherosclerosis and hypercholesterolemia
|
US20040116510A1
(en)
*
|
2002-03-05 |
2004-06-17 |
Nichtberger Steven A. |
Antihypertensive agent and cholesterol absorption inhibitor combination therapy
|
US20030204096A1
(en)
*
|
2002-03-25 |
2003-10-30 |
Schering Corporation |
Enantioselective synthesis of azetidinone intermediate compounds
|
DE10227508A1
(de)
*
|
2002-06-19 |
2004-01-08 |
Aventis Pharma Deutschland Gmbh |
Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
GB0215579D0
(en)
*
|
2002-07-05 |
2002-08-14 |
Astrazeneca Ab |
Chemical compounds
|
JP4579681B2
(ja)
*
|
2002-07-09 |
2010-11-10 |
ブリストル−マイヤーズ スクイブ カンパニー |
抗糖尿病薬および抗肥満薬として有用な置換ヘテロシクロ誘導体および方法
|
US7135556B2
(en)
*
|
2002-07-19 |
2006-11-14 |
Schering Corporation |
NPC1L1 (NPC3) and methods of use thereof
|
US20040132058A1
(en)
|
2002-07-19 |
2004-07-08 |
Schering Corporation |
NPC1L1 (NPC3) and methods of use thereof
|
AR040588A1
(es)
*
|
2002-07-26 |
2005-04-13 |
Schering Corp |
Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
|
US6933292B2
(en)
*
|
2002-07-30 |
2005-08-23 |
Children's Medical Center Corporation |
Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
|
WO2004056727A2
(fr)
*
|
2002-12-19 |
2004-07-08 |
Atherogenics, Inc. |
Procede de fabrication de derives de chalcone
|
EP1601668B1
(fr)
|
2003-03-07 |
2008-08-27 |
Schering Corporation |
Composes d'azetidinone substitues, leurs formulations et utilisations en vue du traitement de l'hypercholesterolemie
|
ES2318274T3
(es)
*
|
2003-03-07 |
2009-05-01 |
Schering Corporation |
Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia.
|
CA2517573C
(fr)
*
|
2003-03-07 |
2011-12-06 |
Schering Corporation |
Composes d'azetidinone substitues, formulations et utilisations de ceux-ci pour traiter l'hypercholesterolemie
|
EP1626954A2
(fr)
*
|
2003-05-05 |
2006-02-22 |
Ranbaxy Laboratories, Ltd. |
Procede pour la preparation de trans-isomeres de derives de diphenylazetidinone
|
AR041089A1
(es)
|
2003-05-15 |
2005-05-04 |
Merck & Co Inc |
Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
|
JP4901474B2
(ja)
*
|
2003-05-30 |
2012-03-21 |
ランバクシー ラボラトリーズ リミテッド |
置換ピロール誘導体
|
US20060148721A1
(en)
*
|
2003-06-06 |
2006-07-06 |
Erondu Ngozi E |
Combination therapy for the treatment of dyslipidemia
|
CA2533392A1
(fr)
*
|
2003-07-24 |
2005-02-03 |
Merck & Co., Inc. |
Cycloalcanes diphenyl-substitutes, compositions contenant ces composes, et procedes d'utilisation
|
WO2005009955A1
(fr)
*
|
2003-07-31 |
2005-02-03 |
Hetero Drugs Limited |
Polymorphes de l'ezetimibe
|
EP1522541A1
(fr)
*
|
2003-10-07 |
2005-04-13 |
Lipideon Biotechnology AG |
Nouveaux composés hypocholesterolémiques
|
WO2005042692A2
(fr)
*
|
2003-10-31 |
2005-05-12 |
Forbes Medi-Tech Inc. |
Methode permettant d'inhiber l'expression de genes qui induisent l'influx de cholesterol cellulaire dans les cellules animales et d'inhiber la production de proteines issues de l'expression de ces genes
|
EP1918000A2
(fr)
|
2003-11-05 |
2008-05-07 |
Schering Corporation |
Combinaisons d'agents de modulation lipide et azétidinones substitués et traitements pour conditions vasculaires
|
CA2544309A1
(fr)
*
|
2003-11-05 |
2005-05-26 |
Schering Corporation |
Combinaisons de modulateurs lipidiques et d'azetidinones substituees et traitements d'affections vasculaires
|
PT1682499E
(pt)
*
|
2003-11-10 |
2007-11-05 |
Microbia Inc |
4-biarilil-1-fenilazetidin-2-onas
|
US7067675B2
(en)
*
|
2003-11-24 |
2006-06-27 |
Hetero Drugs Limited |
Process for ezetimibe intermediate
|
WO2005061452A1
(fr)
*
|
2003-12-23 |
2005-07-07 |
Astrazeneca Ab |
Derives diphenylazetidinone a activite inhibitrice de l'absorption du cholesterol
|
EP1699760B1
(fr)
*
|
2003-12-23 |
2017-05-17 |
Merck Sharp & Dohme Corp. |
Composes anti-hypercholesterolemie
|
GB0329778D0
(en)
*
|
2003-12-23 |
2004-01-28 |
Astrazeneca Ab |
Chemical compounds
|
US7901893B2
(en)
*
|
2004-01-16 |
2011-03-08 |
Merck Sharp & Dohme Corp. |
NPC1L1 (NPC3) and methods of identifying ligands thereof
|
CA2558766A1
(fr)
|
2004-03-05 |
2005-09-22 |
The Trustees Of The University Of Pennsylvania |
L'utilisation d'inhibiteurs mtp pour le traitement a faibles effets secondaires contre des affections liees a l'hyperlipidemie et l'hypercholesterolemie
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
US20050244367A1
(en)
*
|
2004-05-03 |
2005-11-03 |
Ilypsa, Inc. |
Phospholipase inhibitors localized in the gastrointestinal lumen
|
MXPA06013456A
(es)
*
|
2004-05-21 |
2007-03-01 |
Sanofi Aventis Deutschland |
Metodo para producir derivados de 1,4-difenilazetidinona.
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
US20060063828A1
(en)
*
|
2004-06-28 |
2006-03-23 |
Weingarten M D |
1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
|
US20070244107A1
(en)
*
|
2004-08-25 |
2007-10-18 |
Waters M Gerard |
Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
|
US20060046996A1
(en)
|
2004-08-31 |
2006-03-02 |
Kowa Co., Ltd. |
Method for treating hyperlipidemia
|
AR050631A1
(es)
*
|
2004-09-09 |
2006-11-08 |
Novartis Ag |
Combinacion de compuestos organicos
|
EP1807070A1
(fr)
*
|
2004-09-29 |
2007-07-18 |
Schering Corporation |
Combinaisons d'azetidinones substituees et d'antagonistes cb1
|
CA2589483C
(fr)
|
2004-12-03 |
2013-10-29 |
Schering Corporation |
Piperazines substituees en tant qu'antagonistes de cb1
|
JP2008523807A
(ja)
*
|
2004-12-15 |
2008-07-10 |
シェーリング コーポレイション |
コレステロール吸収インヒビターについての機能アッセイ
|
US20130082232A1
(en)
|
2011-09-30 |
2013-04-04 |
Unity Semiconductor Corporation |
Multi Layered Conductive Metal Oxide Structures And Methods For Facilitating Enhanced Performance Characteristics Of Two Terminal Memory Cells
|
US8361999B2
(en)
|
2005-04-04 |
2013-01-29 |
Pontificia Universidad Catolica De Chile |
Methods of treating cholesterol gallstone disease with ezetimibe
|
TW200726746A
(en)
|
2005-05-06 |
2007-07-16 |
Microbia Inc |
Processes for production of 4-biphenylylazetidin-2-ones
|
CN101212978A
(zh)
*
|
2005-05-09 |
2008-07-02 |
迈克罗比亚公司 |
有机金属苯基膦酸酯偶联剂
|
AU2006244043A1
(en)
*
|
2005-05-11 |
2006-11-16 |
Microbia, Inc. |
Processes for production of phenolic 4-biphenylylazetidin-2-ones
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
BRPI0611415A2
(pt)
*
|
2005-05-25 |
2010-09-08 |
Microbia Inc |
ácidos fosfÈnicos de 4-(bifenilil)azetidin-2-ona e processo para a produção dos mesmos
|
CN101198338A
(zh)
*
|
2005-06-15 |
2008-06-11 |
默克公司 |
抗高胆固醇血化合物
|
AU2006262441A1
(en)
*
|
2005-06-20 |
2007-01-04 |
Schering Corporation |
Piperidine derivatives useful as histamine H3 antagonists
|
AR054482A1
(es)
*
|
2005-06-22 |
2007-06-27 |
Astrazeneca Ab |
Derivados de azetidinona para el tratamiento de hiperlipidemias
|
US8013150B2
(en)
*
|
2005-06-22 |
2011-09-06 |
Msn Laboratories Ltd. |
Process for the preparation of ezetimibe
|
SA06270191B1
(ar)
*
|
2005-06-22 |
2010-03-29 |
استرازينيكا ايه بي |
مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
|
EP1741427A1
(fr)
*
|
2005-07-06 |
2007-01-10 |
KRKA, D.D., Novo Mesto |
Composition pharmaceutique comprenant la simvastatin et l'ezetimibe
|
US20070049748A1
(en)
*
|
2005-08-26 |
2007-03-01 |
Uppala Venkata Bhaskara R |
Preparation of ezetimibe
|
KR20070063592A
(ko)
|
2005-09-08 |
2007-06-19 |
테바 파마슈티컬 인더스트리즈 리미티드 |
에제티밉의 합성을 위한 중간체인(3r,4s)-4-((4-벤질옥시)페닐)-1-(4-플루오로페닐)-3-((s)-3-(4-플루오로페닐)-3-히드록시프로필)-2-아제티디논의제조 방법
|
TW200806623A
(en)
*
|
2005-10-05 |
2008-02-01 |
Merck & Co Inc |
Anti-hypercholesterolemic compounds
|
RU2008119687A
(ru)
|
2005-10-21 |
2009-11-27 |
Новартис АГ (CH) |
Комбинации органических соединений
|
AU2006313430B2
(en)
*
|
2005-11-08 |
2012-09-06 |
Ranbaxy Laboratories Limited |
Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
HUP0501164A2
(en)
*
|
2005-12-20 |
2007-07-30 |
Richter Gedeon Nyrt |
New industrial process for the production of ezetimibe
|
MX2008008340A
(es)
*
|
2005-12-21 |
2008-09-03 |
Schering Corp |
Tratamiento de enfermedad de higado graso no alcoholica usando agentes reductores de colesterol y/o antagonista/agonista inverso de receptor de histamina 3.
|
ATE445596T1
(de)
*
|
2005-12-22 |
2009-10-15 |
Medichem Sa |
Verfahren zur herstellung von zwischenprodukten für die herstellung von ezetimibe
|
CA2637565A1
(fr)
|
2006-01-18 |
2007-07-26 |
Schering Corporation |
Modulateurs de recepteurs de cannibinoides
|
MX2008010235A
(es)
*
|
2006-02-16 |
2008-10-23 |
Kotobuki Pharmaceutical Co Ltd |
Metodo para producir alcohol opticamente activo.
|
US7910698B2
(en)
|
2006-02-24 |
2011-03-22 |
Schering Corporation |
NPC1L1 orthologues
|
RU2008136765A
(ru)
*
|
2006-03-06 |
2010-04-20 |
Тева Фармасьютикл Индастриес Лтд. (Il) |
Композиции эзетимиба
|
WO2008020314A2
(fr)
*
|
2006-03-14 |
2008-02-21 |
Ranbaxy Laboratories Limited |
Formulations de dosage stabilisantes à base de statine
|
US20080032964A1
(en)
*
|
2006-04-10 |
2008-02-07 |
Kansal Vinod K |
Process for the synthesis of azetidinone
|
AR060623A1
(es)
*
|
2006-04-27 |
2008-07-02 |
Astrazeneca Ab |
Compuestos derivados de 2-azetidinona y un metodo de preparacion
|
US20070275052A1
(en)
*
|
2006-05-24 |
2007-11-29 |
Glenmark Pharmaceuticals Limited |
Pharmaceutical compositions containing sterol inhibitors
|
AR063469A1
(es)
*
|
2006-07-14 |
2009-01-28 |
Ranbaxy Lab Ltd |
Formas polimorficas de ácido (3r,5r)-7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3, 5-dihidroxi-heptanoico, sal hemicalcio, metodos de preparacion de las mismas, una composicion farmaceutica que las comprende y su uso en el tratamiento de enfermedades
|
WO2008027081A1
(fr)
*
|
2006-08-29 |
2008-03-06 |
Teva Pharmaceutical Industries Ltd. |
Procédés de purification de la (3r,4s)-4-(4-hydroxy-protégé-phényl)-1-(4-fluorophényl)-3-(4-fluorophényl)-3-oxopropyl]azétidin-2-one
|
US20080103122A1
(en)
*
|
2006-09-05 |
2008-05-01 |
Schering Corporation |
Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
|
US20080076750A1
(en)
*
|
2006-09-15 |
2008-03-27 |
Aslanian Robert G |
Azetidinone Derivatives and Methods of Use Thereof
|
CN101583612A
(zh)
*
|
2006-09-15 |
2009-11-18 |
先灵公司 |
治疗脂质代谢障碍的氮杂环丁酮衍生物
|
US7902157B2
(en)
|
2006-09-15 |
2011-03-08 |
Schering Corporation |
Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
|
US20080070890A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Burnett Duane A |
Spirocyclic Azetidinone Compounds and Methods of Use Thereof
|
AR062790A1
(es)
*
|
2006-09-15 |
2008-12-03 |
Schering Corp |
Derivados de azetidina utiles en el tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos
|
US20080085315A1
(en)
*
|
2006-10-10 |
2008-04-10 |
John Alfred Doney |
Amorphous ezetimibe and the production thereof
|
CN100564357C
(zh)
*
|
2006-10-20 |
2009-12-02 |
浙江天宇药业有限公司 |
一种氮杂环丁酮衍生物及其合成方法
|
US20100035857A1
(en)
*
|
2006-12-20 |
2010-02-11 |
Devita Robert J |
Anti-hypercholesterolemic compounds
|
JP2010513534A
(ja)
*
|
2006-12-21 |
2010-04-30 |
エージェリオン ファーマシューティカルズ, インコーポレイテッド |
Mtpインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
|
EP1939174A1
(fr)
*
|
2006-12-21 |
2008-07-02 |
LEK Pharmaceuticals D.D. |
Complexe d'inclusion d'ezetimibe et une cyclodextrine et procédés pour son préparation
|
US20130190487A1
(en)
*
|
2007-01-24 |
2013-07-25 |
Krka |
Process for the preparation of ezetimibe and derivatives thereof
|
WO2008096372A2
(fr)
*
|
2007-02-06 |
2008-08-14 |
Ind-Swift Laboratories Limited |
Procédé de préparation de l'ézétimibe extrêmement pur au moyen de nouveaux intermédiaires
|
WO2008104875A1
(fr)
*
|
2007-03-01 |
2008-09-04 |
Pfizer Products Inc. |
Oxazolidinones comme inhibiteurs d'absorption de cholestérol
|
CA2675312A1
(fr)
|
2007-03-06 |
2008-09-12 |
Teijin Pharma Limited |
Derives de 1-biarylazetidinone
|
WO2008112166A2
(fr)
|
2007-03-09 |
2008-09-18 |
Indigene Pharmaceuticals Inc. |
Combinaison de metformine r-(+) lipoate et d'agents antihyperlipidémiques pour le traitement de l'hyperglycémie diabétique et de complications diabétiques
|
WO2008123953A1
(fr)
*
|
2007-04-02 |
2008-10-16 |
Merck & Co., Inc. |
Composé anti-hypercholestérolémique
|
US20100197564A1
(en)
*
|
2007-04-19 |
2010-08-05 |
Schering Corporation |
Diaryl morpholines as cb1 modulators
|
US8048880B2
(en)
*
|
2007-05-03 |
2011-11-01 |
Anthera Pharmaceuticals, Inc. |
Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
|
US20090047716A1
(en)
*
|
2007-06-07 |
2009-02-19 |
Nurit Perlman |
Reduction processes for the preparation of ezetimibe
|
US20080318920A1
(en)
*
|
2007-06-19 |
2008-12-25 |
Protia, Llc |
Deuterium-enriched ezetimibe
|
US20080319221A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Bernd Junker |
Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
|
US20080319218A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Andreas Haubrich |
Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
|
WO2009005671A2
(fr)
*
|
2007-06-28 |
2009-01-08 |
Schering Corporation |
Pipérazines à substitution servant d'antagonistes des récepteurs cb1
|
RU2010102478A
(ru)
*
|
2007-06-28 |
2011-08-10 |
Интэрвэт Интэрнэшнл Б.Ф. (NL) |
Замещенные пиперазины как антагонисты св1
|
CA2694378A1
(fr)
*
|
2007-07-27 |
2009-02-05 |
Cipla Limited |
Compositions pharmaceutiques et leur procede de preparation
|
WO2009024889A2
(fr)
|
2007-08-21 |
2009-02-26 |
Ranbaxy Laboratories Limited |
Composition pharmaceutique comprenant un inhibiteur de réductase hmg-coa et un ézétimibe
|
WO2009032264A1
(fr)
*
|
2007-08-30 |
2009-03-12 |
Teva Pharmaceutical Industries Ltd. |
Procédés de préparation d'intermédiaires d'ézétimibe par réduction microbienne
|
WO2009027785A2
(fr)
*
|
2007-08-30 |
2009-03-05 |
Pfizer Products Inc. |
Composés pharmaceutiques et dérivés
|
DE102007054497B3
(de)
*
|
2007-11-13 |
2009-07-23 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
|
EP2217214B1
(fr)
|
2007-12-10 |
2017-07-19 |
ratiopharm GmbH |
Formulation pharmaceutique comprenant de l'ézétimibe
|
CZ305066B6
(cs)
*
|
2008-02-25 |
2015-04-22 |
Zentiva, K.S. |
Způsob výroby (3R,4S)-1-(4-fluorfenyl)-3-[(3S)-3-(4-fluorfenyl)-3-hydroxypropyl)]-4-(4-hydroxyfenyl)-2-azetidinonu
|
EP2128133A1
(fr)
|
2008-05-26 |
2009-12-02 |
Lek Pharmaceuticals D.D. |
Procédé et composition d'ézétimibe
|
US20110077232A1
(en)
*
|
2008-06-06 |
2011-03-31 |
Nicox S.A. |
Compositions comprising atorvastatin 4-(nitrooxy) butyl ester and a hypolipidemic drug
|
US20090312302A1
(en)
*
|
2008-06-17 |
2009-12-17 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
|
CN102186972B
(zh)
|
2008-08-29 |
2014-08-20 |
科德克希思公司 |
用于立体选择性生产(4s)-3-[(5s)-5-(4-氟苯基)-5-羟基戊酰基]-4-苯基-1,3-噁唑烷-2-酮的酮还原酶多肽
|
EP2355812B1
(fr)
|
2008-11-14 |
2019-07-10 |
Bomi P. Framroze |
Diminuer le taux circulant du complexe lipoprotéine de basse densité oxydée/bêta-2-glycoprotéine 1 pour le traitement de l'athérosclérose
|
EP2204170A1
(fr)
|
2008-12-01 |
2010-07-07 |
LEK Pharmaceuticals D.D. |
Composition pharmaceutique comprenant ézétimide et simvastatine
|
EP2379562A1
(fr)
|
2008-12-16 |
2011-10-26 |
Schering Corporation |
Dérivés de pyranone bicyclique comme agonistes du récepteur de l'acide nicotinique
|
EP2379547A1
(fr)
|
2008-12-16 |
2011-10-26 |
Schering Corporation |
Dérivés de pyridopyrimidine et leurs procédés d'utilisation
|
EP2216016A1
(fr)
|
2009-02-06 |
2010-08-11 |
LEK Pharmaceuticals d.d. |
Procédé pour la préparation d'une composition pharmaceutique comprenant de l'ézétimibe
|
WO2010100255A1
(fr)
|
2009-03-06 |
2010-09-10 |
Lipideon Biotechnology Ag |
Compositions pharmaceutiques hypocholestérolémiques
|
PL2229938T3
(pl)
|
2009-03-13 |
2012-09-28 |
Sanovel Ilac Sanayi Ve Ticaret As |
Kompozycje ezetymibu
|
US9040688B2
(en)
|
2009-03-31 |
2015-05-26 |
Lupin Limited |
Intermediates in the preparation of 1,4-diphenyl azetidinone
|
WO2010113175A2
(fr)
|
2009-04-01 |
2010-10-07 |
Matrix Laboratories Ltd |
Procédé enzymatique pour la préparation de la (s)-5-(4-fluorophényl)-5-hydroxy-1-morpholin-4-yl-pentan-1-one, un intermédiaire de l'ézétimibe et la conversion ultérieure en ézétimibe
|
WO2011002424A2
(fr)
|
2009-07-02 |
2011-01-06 |
Bilgic Mahmut |
Préparation pharmaceutique améliorant la solubilité et la stabilité
|
EP2448919A2
(fr)
|
2009-07-02 |
2012-05-09 |
Mahmut Bilgic |
Formulation pharmaceutique permettant d'augmenter la solubilité et la stabilité
|
WO2011002422A2
(fr)
|
2009-07-02 |
2011-01-06 |
Bilgic Mahmut |
Formulation pharmaceutique améliorant la solubilité
|
CN101993403B
(zh)
*
|
2009-08-11 |
2012-07-11 |
浙江海正药业股份有限公司 |
氮杂环丁酮类化合物及医药应用
|
SG178456A1
(en)
|
2009-08-19 |
2012-04-27 |
Codexis Inc |
Ketoreductase polypeptides for the preparation of phenylephrine
|
BR112012021444A2
(pt)
|
2010-02-24 |
2016-05-31 |
Relypsa Inc |
polímero de amina reticulado, composição farmacêutica, método de redução do colesterol ldl sérico em um indivíduo, métodos para tratar doença, de remoção de sais biliares de um indivíduo, e para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de aminas.
|
JP5964247B2
(ja)
|
2010-02-24 |
2016-08-03 |
レリプサ, インコーポレイテッド |
胆汁酸捕捉剤として使用するためのポリイミダゾール
|
RU2612795C2
(ru)
|
2010-02-24 |
2017-03-13 |
Релипса, Инк. |
Аминосодержащие полимеры для применения в качестве секвестрантов желчных кислот
|
EP2368543A1
(fr)
|
2010-03-25 |
2011-09-28 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Procédé de préparation de composition pharmaceutique granulée comprenant de la simvastatine et/ou ézétimibe
|
CA2995446C
(fr)
|
2010-04-23 |
2020-05-12 |
Synageva Biopharma Corp |
Enzyme des maladies lysosomales
|
EP2566497B1
(fr)
|
2010-05-04 |
2015-07-29 |
Codexis, Inc. |
Biocatalyseurs pour la synthèse d'ézétimibe
|
ES2372460B1
(es)
|
2010-07-09 |
2012-11-16 |
Moehs Ibérica S.L. |
Nuevo método para la preparación de ezetimiba.
|
BR122019021757B1
(pt)
|
2010-09-09 |
2020-12-08 |
Alexion Pharmaceuticals, Inc |
composição farmacêutica para tratamento de um paciente humano sofrendo de uma deficiência de lipase ácida lisossomal (lal)
|
DK3400944T3
(da)
|
2010-11-08 |
2020-10-12 |
Albireo Ab |
Ibat-inhibitorer til behandling af leversygdomme
|
PL2637646T3
(pl)
|
2010-11-08 |
2017-01-31 |
Albireo Ab |
Kombinacja farmaceutyczna zawierająca inhibitor ibat i środek wiążący kwasy żółciowe
|
WO2012076030A1
(fr)
|
2010-12-10 |
2012-06-14 |
Pharmathen S.A. |
Procédé de préparation de composés intermédiaires utiles dans la préparation de l'ézétimibe
|
WO2012112681A1
(fr)
|
2011-02-15 |
2012-08-23 |
Shire Human Genetic Therapies, Inc. |
Procédés de traitement d'un déficit en lipase acide lysosomale
|
US8455474B2
(en)
|
2011-03-04 |
2013-06-04 |
Mackay Memorial Hospital |
Method for treating tuberculosis
|
WO2012155932A1
(fr)
|
2011-05-17 |
2012-11-22 |
Pharmathen S.A. |
Procédé amélioré pour la préparation d'ézétimibe
|
PL231215B1
(pl)
|
2011-06-15 |
2019-02-28 |
Inst Chemii Organicznej Polskiej Akademii Nauk |
Sposób wytwarzania podstawionych azetydynonów oraz związków pośrednich do ich syntezy
|
CN102675177A
(zh)
*
|
2011-06-28 |
2012-09-19 |
常州制药厂有限公司 |
一种降血脂药物及其关键中间体的制备方法
|
CN102952055A
(zh)
*
|
2011-08-16 |
2013-03-06 |
凯瑞斯德生化(苏州)有限公司 |
一种依泽替米贝和其中间体的制备方法
|
CN103204795B
(zh)
*
|
2012-01-11 |
2016-12-14 |
重庆华邦胜凯制药有限公司 |
一种手性氮杂环丁酮类化合物的制备方法
|
MX365046B
(es)
|
2012-05-01 |
2019-05-17 |
Althera Life Sciencies Llc |
Formulacion de tableta oral que consiste de una combinacion fija de rosuvastatina y ezetimiba para el tratamiento de hiperlipidemia y enfermedades cardiovasculares.
|
CN103570574B
(zh)
|
2012-07-20 |
2016-04-13 |
中国科学院上海有机化学研究所 |
一种依泽替米贝的合成方法及该方法中所用的中间体
|
CN103102297A
(zh)
*
|
2012-09-28 |
2013-05-15 |
北京赛林泰医药技术有限公司 |
一种新的依折麦布的合成方法
|
TW201427658A
(zh)
|
2012-12-10 |
2014-07-16 |
Merck Sharp & Dohme |
藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
|
CN103864708A
(zh)
*
|
2012-12-12 |
2014-06-18 |
天津市医药集团技术发展有限公司 |
一种依折麦布中间体的制备方法
|
WO2015039675A1
(fr)
|
2013-09-23 |
2015-03-26 |
Pharmathen S.A. |
Nouveau procédé de préparation d'intermédiaires d'ézétimibe
|
US9649294B2
(en)
|
2013-11-04 |
2017-05-16 |
Merck Sharp & Dohme Corp. |
Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
|
WO2015092448A1
(fr)
|
2013-12-18 |
2015-06-25 |
Rudjer Boskovic Institute |
Inhibiteurs de l'absorption du cholestérol de type bêta-lactamines
|
CN103739537B
(zh)
*
|
2013-12-24 |
2015-05-20 |
连云港恒运医药科技有限公司 |
依折麦布的新合成方法
|
KR20150079373A
(ko)
|
2013-12-30 |
2015-07-08 |
한미약품 주식회사 |
에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
|
CN103755616A
(zh)
*
|
2013-12-31 |
2014-04-30 |
北京万全德众医药生物技术有限公司 |
一种制备依泽替米贝异构体的方法
|
EP3148587B1
(fr)
|
2014-05-30 |
2021-02-24 |
Pfizer Inc |
Dérivés carbonitriles en tant que modulateurs sélectifs du récepteur des androgènes
|
CN105294426B
(zh)
|
2014-06-09 |
2019-05-14 |
浙江海正药业股份有限公司 |
氮杂环丁酮化合物制备方法及其中间体
|
CN104447474A
(zh)
*
|
2014-11-11 |
2015-03-25 |
武汉武药科技有限公司 |
一种依折麦布异构体的合成方法
|
CN104387308A
(zh)
*
|
2014-11-18 |
2015-03-04 |
武汉福星生物药业有限公司 |
一种控制EZ-zanOH杂质产生制备高纯度依折麦布的方法
|
CN104513187B
(zh)
*
|
2015-01-09 |
2017-05-31 |
安润医药科技(苏州)有限公司 |
依折麦布及其中间体的合成方法
|
JP2016145173A
(ja)
*
|
2015-02-09 |
2016-08-12 |
株式会社トクヤマ |
(3r,4s)‐1‐(4‐フルオロフェニル)‐[3(s)‐ヒドロキシ‐3‐(4‐フルオロフェニル)プロピル]‐(4‐ヒドロキシフェニル)‐2‐アゼチジノンの製造方法
|
US10912751B2
(en)
|
2015-03-13 |
2021-02-09 |
Esperion Therapeutics, Inc. |
Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
|
MA41793A
(fr)
|
2015-03-16 |
2018-01-23 |
Esperion Therapeutics Inc |
Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
|
CN105287513A
(zh)
*
|
2015-10-23 |
2016-02-03 |
浙江永宁药业股份有限公司 |
一种依折麦布药物组合物及其制备方法
|
CN107098841A
(zh)
*
|
2016-02-19 |
2017-08-29 |
常州方楠医药技术有限公司 |
一种依折麦布的制备方法及该方法中所用的中间体
|
JP6883664B2
(ja)
|
2016-12-05 |
2021-06-09 |
パットスナップ リミテッド |
大規模データベース内で論じられる化学構造の類似性に従って大規模データベースで利用可能な情報を検索及び表示するためのシステム
|
US20180338922A1
(en)
|
2017-05-26 |
2018-11-29 |
Esperion Therapeutics, Inc. |
Fixed dose formulations
|
EP3437636A1
(fr)
|
2017-08-02 |
2019-02-06 |
Adamed sp. z o.o. |
Composition pharmaceutique comprenant de l'ézétimibe
|
US11408274B2
(en)
|
2018-01-16 |
2022-08-09 |
Q.E.D. Environmental Systems, Inc. |
Fluid level monitoring system and method incorporating pressure sensor system having inflatable/collapsible bag
|
EP3942047A1
(fr)
|
2019-03-20 |
2022-01-26 |
Regeneron Pharmaceuticals, Inc. |
Traitement de niveaux de lipides accrus avec des inhibiteurs de protéine d'activation de clivage de protéine de liaison d'élément régulateur de stérol (scap)
|
WO2020191141A1
(fr)
|
2019-03-20 |
2020-09-24 |
Regeneron Pharmaceuticals, Inc. |
Traitement de niveaux de lipides accrus avec des inhibiteurs du facteur de transcription 1 de liaison à un élément régulateur de stérol (srebf1)
|
BR112022001783A2
(pt)
|
2019-07-31 |
2022-03-22 |
Tecnimede Soc Tecnico Medicinal Sa |
Composições orais sólidas multiunitárias de liberação imediata, seus métodos e usos.
|
EP4188338A1
(fr)
|
2020-07-27 |
2023-06-07 |
KRKA, d.d., Novo mesto |
Comprimé bicouche comprenant de l'ézétimibe et de l'atorvastatine
|
EP4357333A1
(fr)
*
|
2021-06-17 |
2024-04-24 |
Zhejiang Hisun Pharmaceutical Co., Ltd. |
Intermédiaire d'hystéétimibe et son procédé de préparation
|
WO2023275715A1
(fr)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Métabolites de modulateurs sélectifs du récepteur des androgènes
|